Dendritic cell vaccine as a potential strategy to end the COVID-19 pandemic. Why should it be Ex Vivo?
Expert Rev Vaccines
; 21(8): 1111-1120, 2022 08.
Article
in English
| MEDLINE | ID: covidwho-1860689
ABSTRACT
INTRODUCTION:
Developing a safe and efficacious vaccine that can induce broad and long-term immunity for SARS-CoV-2 infection is the most critical research to date. As the most potent APCs, dendritic cells (DCs) can induce a robust T cell immunity. In addition, DCs also play an essential role in COVID-19 pathogenesis, making them a potential vaccination target. However, the DCs-based vaccine with ex vivo loading has not yet been explored for COVID-19. AREAS COVERED This review aims to provide the rationale for developing a DCs-based vaccine with ex vivo loading of SARS-CoV-2 antigen. Here, we discuss the role of DCs in immunity and the effect of SARS-CoV-2 infection on DCs. Then, we propose the mechanism of the DCs-based vaccine in inducing immunity and highlight the benefits of ex vivo loading of antigen. EXPERT OPINION We make the case that an ex vivo loaded DC-based vaccination is appropriate for COVID-19 prevention.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cancer Vaccines
/
COVID-19
Type of study:
Observational study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Expert Rev Vaccines
Journal subject:
Allergy and Immunology
Year:
2022
Document Type:
Article
Affiliation country:
14760584.2022.2080658
Similar
MEDLINE
...
LILACS
LIS